Dose steps
Wegovy 7.2 mg (Wegovy HD): what is different?
It is a higher weekly dose, in its own Wegovy HD pen, for adults who have tolerated 2.4 mg for at least 4 weeks when the prescriber judges more is needed. The average blood level is about 230 nmol/L against about 75 at 2.4 mg, and one side effect stands out: altered skin sensations, in 22 percent of people on 7.2 mg.
The Oolite team, from the FDA labels
Sources checked Oct 27, 2026
Published Nov 13, 2026
Updated Oct 27, 2026 · 3 min read
The short answer
It is a higher weekly dose, in its own Wegovy HD pen, for adults who have tolerated 2.4 mg for at least 4 weeks when the prescriber judges more is needed. The average blood level is about 230 nmol/L against about 75 at 2.4 mg, and one side effect stands out: altered skin sensations, in 22 percent of people on 7.2 mg.
What the label says
The dosing section (§2.2) places 7.2 mg after the usual maintenance dose, for one indication only:
From the labelFor patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.
It is the top of the shot's schedule, and it is a choice, not a step everyone takes: the label still calls 2.4 mg the recommended maintenance dose for weight reduction in adults. It is for adults only:
From the labelThe safety of WEGOVY® tablets and WEGOVY® 7.2 mg injection have not been established in pediatric patients or patients with MASH.
The dose comes in its own pen, listed in §3 as 7.2 mg/0.75 mL (Wegovy HD), a single-dose pen. Its instructions say what to check before each shot:
From the labelAlways check you have the medicine and dose that your healthcare provider prescribed.
A higher level in the blood
The pharmacology section (§12.3) gives the level at each dose. At 2.4 mg, the average steady state is about 75 nmol/L. At 7.2 mg:
From the labelThe average semaglutide steady state concentration following subcutaneous administration of WEGOVY® 7.2 mg once weekly injection was approximately 230 nmol/L in patients with obesity
From the labelThe steady state exposure concentrations increased proportionally with doses up to 7.2 mg once weekly.
The half-life does not change. Semaglutide is still present for about 5 to 7 weeks after the last injectable dose, whether that dose was 2.4 mg or 7.2 mg.
The skin effect
Most of the side effects at 7.2 mg are the familiar ones, a little more often: in the trials, nausea in 39 percent against 35 percent on 2.4 mg and 13 percent on placebo, vomiting in 22 against 16 and 6. One line of the side effect table (Table 4) changes scale: dysesthesia, 0 percent on placebo, 6 percent on 2.4 mg, 22 percent on 7.2 mg. The label groups under that word burning, tingling, sensitive or painful skin and similar sensations.
From the labelIn clinical trials evaluating patients with and without type 2 diabetes mellitus, WEGOVY® 7.2 mg injection dysesthesia was reported at a higher rate in the WEGOVY® 7.2 mg injection group (22%), compared to WEGOVY® 2.4 mg injection (6%) and placebo (0.3%).
From the labelThe incidence of dysesthesia with WEGOVY® increased with increasing dosage and drug levels in the blood.
The label also follows what happened next. Among 288 people with dysesthesia on 7.2 mg, 2 percent stopped treatment, 8 percent paused it and 23 percent had their dose lowered, and most of those recovered. Some went back up to 7.2 mg afterwards:
From the labelOf these 38 patients, 17 (45%) subsequently reported recurrence of dysesthesia.
Hair loss
Hair loss is the other line that rises:
From the labelIn clinical trials with WEGOVY® 7.2 mg injection, hair loss was reported in 5.8% of patients treated with WEGOVY® 7.2 mg (8.4% female, 0.2% male), 3.3% of patients treated with WEGOVY® 2.4 mg (5.4% female, 0 male), and 1.0% of patients on placebo (1.5% female, 0 male).
Overall, 5 percent of people on 7.2 mg stopped treatment because of side effects, the same as on 2.4 mg, against 2 percent on placebo.
A skin sensation that starts after the step up, and how much it bothers you, is the kind of thing your prescriber needs dated. Oolite's shot log keeps each dose and each side effect with its day, and the report for your prescriber shows them side by side.
Questions people ask
Who can move up to 7.2 mg?
The label reserves it for adults on Wegovy for weight reduction who have tolerated 2.4 mg for at least 4 weeks, when additional reduction is clinically indicated. For cardiovascular risk reduction, the maintenance dose stays 2.4 mg or 1.7 mg. The decision is your prescriber's.
Is it a different pen?
Yes. The label lists the 7.2 mg dose as Wegovy HD, a single-dose pen holding 7.2 mg in 0.75 mL, the same volume as the 2.4 mg pen. The single-dose syringe stops at 2.4 mg. The Wegovy HD instructions ask you to check you have the medicine and dose your healthcare provider prescribed.
What is the skin effect?
The label calls it dysesthesia: burning, tingling, sensitive or painful skin and related sensations. It was reported by 22 percent of people on 7.2 mg, 6 percent on 2.4 mg and 0.3 percent on placebo. In most people whose treatment was adjusted, it went away.
Does 7.2 mg stay in the body longer?
The label gives the same figure for both doses: semaglutide is present in the circulation for about 5 to 7 weeks after the last injectable dose of 2.4 mg or 7.2 mg. The level is higher, the half-life is the same, about 1 week.
Sources
- Wegovy prescribing information, Novo Nordisk, §2.2, §3, §6.1, §8.4 and §12.3, revised 06/2026 · 7.2 mg after tolerating 2.4 mg for at least 4 weeks when additional reduction is clinically indicated; Wegovy HD 7.2 mg/0.75 mL single-dose pen; Table 4 (placebo, 2.4 mg, 7.2 mg): nausea 13, 35, 39; vomiting 6, 16, 22; dysesthesia 0, 6, 22 percent; dysesthesia 22 vs 6 vs 0.3 percent, 17 of 38 re-escalated patients with recurrence; hair loss 5.8 vs 3.3 vs 1.0 percent; discontinuation for adverse reactions 5, 5 and 2 percent; not established in pediatric patients; steady state about 230 nmol/L at 7.2 mg vs about 75 nmol/L at 2.4 mg; present 5 to 7 weeks after the last dose.
- Wegovy HD Instructions for Use, Novo Nordisk, revised 03/2026 · Wegovy HD comes in one strength, 7.2 mg / 0.75 mL; check you have the medicine and dose your healthcare provider prescribed.
Sources checked Oct 27, 2026. This page is information, not medical advice: read the medical disclaimer, and talk to your prescriber or pharmacist about your own treatment.
Written by
The Oolite team, from the FDA labels
We make Oolite. Every answer starts from the FDA prescribing information, quoted word for word, and is rewritten when a label changes.
How these pages are madeOolite
The GLP-1 tracker for the pill and the shot.
The 30 minute timer, your shot day, the level chart and the dose reminder, on iPhone, with Apple Watch to log. Free to download, then a 14-day free trial.
